Back to today’s briefing

Story perspectives

Vertex Pharmaceuticals Aims to Expand Access to CASGEVY Gene Therapy

6/5/2025

49 7

Summary

Story summary

Vertex Pharmaceuticals is on a mission to make CASGEVY, a groundbreaking gene therapy for sickle cell disease and beta thalassemia, more accessible. Approved by the FDA in late 2023 and early 2024, the $2.2 million treatment faces hurdles like limited treatment centers and complex registration. Vertex is committed to improving access and insurance coverage for patients in need.

1 of 1

Story summary

Vertex Pharmaceuticals is on a mission to make CASGEVY, a groundbreaking gene therapy for sickle cell disease and beta thalassemia, more accessible. Approved by the FDA in late 2023 and early 2024, the $2.2 million treatment faces hurdles like limited treatment centers and complex registration. Vertex is committed to improving access and insurance coverage for patients in need.